{"name":"Xilio Therapeutics","slug":"xilio-therapeutics","ticker":"XLO","exchange":"NASDAQ","domain":"xiliotx.com","description":"Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.","hq":"Waltham, MA","founded":0,"employees":"76","ceo":"","sector":"Immuno-Oncology","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":8.59,"stockChange":0.83,"stockChangePercent":10.7,"marketCap":"$51M","metrics":{"revenue":53484000,"revenueGrowth":331.7,"grossMargin":100,"rdSpend":0,"netIncome":-31300000,"cash":150332992,"dividendYield":0,"peRatio":-14.8,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":43766000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":43766000},{"period":"2024-12-31","value":6344000},{"period":"2023-12-31","value":0},{"period":"2022-12-31","value":0}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":56039000,"rdSpendHistory":[{"period":"2025-12-31","value":56039000},{"period":"2024-12-31","value":41211000},{"period":"2023-12-31","value":52136000},{"period":"2022-12-31","value":59201000}],"sgaSpend":29709000,"operatingIncome":-41982000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-41982000},{"period":"2024-12-31","value":-59645000},{"period":"2023-12-31","value":-79133000},{"period":"2022-12-31","value":-89149000}],"netIncome":-35036000,"netIncomeHistory":[{"period":"2025-12-31","value":-35036000},{"period":"2024-12-31","value":-58241000},{"period":"2023-12-31","value":-76404000},{"period":"2022-12-31","value":-88222000}],"eps":-4.19,"epsHistory":[{"period":"2025-12-31","value":-4.19},{"period":"2024-12-31","value":-15.26},{"period":"2023-12-31","value":-38.92},{"period":"2022-12-31","value":-45.08}],"cash":137531000,"cashHistory":[{"period":"2025-12-31","value":137531000},{"period":"2024-12-31","value":55291000},{"period":"2023-12-31","value":44704000},{"period":"2022-12-31","value":120385000}],"totalAssets":154685000,"totalLiabilities":119412000,"totalDebt":6954000,"equity":35273000,"operatingCashflow":-4992000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-4992000},{"period":"2024-12-31","value":-18378000},{"period":"2023-12-31","value":-68620000},{"period":"2022-12-31","value":-75723000}],"capex":-518000,"capexHistory":[{"period":"2025-12-31","value":-518000},{"period":"2024-12-31","value":-36000},{"period":"2023-12-31","value":-486000},{"period":"2022-12-31","value":-1867000}],"freeCashflow":-5510000,"dividendsPaid":null,"buybacks":null,"employees":76,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":7400000,"ebit":-11836000,"ebitda":-11513000,"period":"2025-12-31","revenue":13686000,"epsBasic":0.959994,"netIncome":10360000,"rdExpense":18122000,"epsDiluted":0.809998,"grossProfit":null,"operatingIncome":-11836000},{"sga":6674000,"ebit":-1929000,"ebitda":-1589000,"period":"2025-09-30","revenue":19066000,"epsBasic":-1.54,"netIncome":-16287000,"rdExpense":14321000,"epsDiluted":-1.54,"grossProfit":null,"operatingIncome":-1929000},{"sga":7120000,"ebit":-14366000,"ebitda":-13985000,"period":"2025-06-30","revenue":8084000,"epsBasic":-2.24,"netIncome":-15844000,"rdExpense":15330000,"epsDiluted":-2.24,"grossProfit":null,"operatingIncome":-14366000},{"sga":8515000,"ebit":-13851000,"ebitda":-13354000,"period":"2025-03-31","revenue":2930000,"epsBasic":-2.52,"netIncome":-13265000,"rdExpense":8266000,"epsDiluted":-2.52,"grossProfit":null,"operatingIncome":-13851000},{"sga":6517000,"ebit":-13629000,"ebitda":-13254000,"period":"2024-12-31","revenue":1724000,"epsBasic":-2.8,"netIncome":-13093000,"rdExpense":8836000,"epsDiluted":-2.8,"grossProfit":null,"operatingIncome":-13629000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":8.59,"previousClose":7.76,"fiftyTwoWeekHigh":16.1,"fiftyTwoWeekLow":6.47,"fiftyTwoWeekRange":"6.468 - 16.1","fiftyDayAverage":8.07,"twoHundredDayAverage":9.36,"beta":0,"enterpriseValue":-97268168,"forwardPE":-14.8,"priceToBook":1.1,"priceToSales":0.96,"enterpriseToRevenue":-1.82,"enterpriseToEbitda":2.38,"pegRatio":0,"ebitda":-40855000,"ebitdaMargin":-76.4,"freeCashflow":-23708876,"operatingCashflow":-56313000,"totalDebt":6638000,"debtToEquity":9.2,"currentRatio":3.59,"returnOnAssets":-19.8,"returnOnEquity":-75.2,"analystRating":"","recommendationKey":"none","numberOfAnalysts":1,"targetMeanPrice":20,"targetHighPrice":20,"targetLowPrice":20,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":28.5,"institutionHeldPercent":33.9,"sharesOutstanding":5982839,"floatShares":3646720,"sharesShort":162958,"shortRatio":5,"shortPercentOfFloat":2.7,"epsTrailing":-2.28,"epsForward":-0.58,"revenuePerShare":9.25,"bookValue":7.79,"officers":[{"age":50,"name":"Dr. Rene  Russo BCPS, Pharm.D.","title":"President, CEO & Director"},{"age":43,"name":"Mr. Christopher  Frankenfield","title":"CFO & COO"},{"age":49,"name":"Dr. Katarina  Luptakova M.D.","title":"Chief Medical Officer"},{"age":55,"name":"Mr. Kevin M. Brennan","title":"Senior Vice President of Finance & Accounting"},{"age":null,"name":"Dr. Uli  Bialucha Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Mr. Nathan  McBride","title":"Chief Information Officer"},{"age":null,"name":"Ms. Caroline  Hensley","title":"Chief Legal Officer"},{"age":null,"name":"Dr. Scott  Coleman Ph.D.","title":"Chief Development Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://xiliotx.com","phone":"857 524 2466"}}